Recurrent gynecological malignant tumor
Conditions
Interventions
High-risk group:Desensitization
Middle-risk group:Monitoring
Low-risk group: Guanchá 2/5000 Observed
Sponsors
Shengjing Hospital Affiliated to China Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) The patient is completely voluntary and autonomous, and signs the research informed consent before entering the group; 2) Histopathology confirmed the recurrence of gynecological malignant tumors; 3) Proposed carboplatin chemotherapy; 4) Aged >= 18 years old and = 12 weeks; 7) Renal function (within the normal range of serum creatinine value); liver function (with AST and ALT within 2 times the upper limit of normal, within the normal range of bilirubin); bone marrow function (leukocytes > 3.0*10^9/L; neutral Granulocytes > 1.5 * 10^9/L; platelets > 100 * 10^9/L; Hb > 80g/L).
Exclusion criteria
Exclusion criteria: 1) Past (within 5 years) or suffering from other uncured malignant tumors; 2) Patients with congenital diseases and infectious diseases; 3) Past or present patients with heart disease class II or above according to the New York Heart Association (NYHA) or patients with congestive heart failure; 4) The investigator believes that it will affect the subject's ability to receive the research program treatment of uncontrolled serious medical diseases, such as combined with serious medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high Blood pressure, uncontrolled infections, active peptic ulcers, etc.; 5) Patients who have experienced severe allergic symptoms with platinum in the past; 6) Patients with central nervous system disease or central nervous system metastasis; 7) The investigator judges that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Allergy classification;Incidence and severity of anaphylaxis; | — |
Countries
China
Contacts
Public ContactXiuqin Li
Shengjing Hospital Affiliated to China Medical University
Outcome results
None listed